CombinatoRx Begins Phase IIa Study of CRx-191 in Psoriasis

November 6, 2007

CombinatoRx has begun dosing in a Phase IIa trial of CRx-191 in psoriasis patients.

CRx-191 is a topical synergistic combination drug candidate for psoriasis and other steroid-responsive dermatoses. The trial will evaluate the efficacy, safety and tolerability of CRx-191 compared with each of its components and placebo in subjects with psoriasis.

The 12-day, single-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of CRx-191 in reducing psoriatic infiltrate band thickness. Approximately 20 subjects will be enrolled.

Endpoints include reduction from baseline in psoriatic infiltrate as measured by ultrasound at day 12, CombinatoRx said.